Aperio Group’s Travere Therapeutics TVTX Stock Holding History

Aperio Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$436K	Buy	15,981 +650	+4%	+$15.2K	﹤0.01%	2032
2020 Q3	$283K	Sell	15,331 -614	-4%	-$11.9K	﹤0.01%	2091
2020 Q2	$325K	Sell	15,945 -5,042	-24%	-$80.3K	﹤0.01%	1987
2020 Q1	$306K	Sell	20,987 -1,760	-8%	-$26.5K	﹤0.01%	1890
2019 Q4	$323K	Buy	22,747 +7,822	+52%	+$99.9K	﹤0.01%	2028
2019 Q3	$173K	Buy	14,925 +5,145	+53%	+$85K	﹤0.01%	2189
2019 Q2	$196K	Sell	9,780 -2,196	-18%	-$43.4K	﹤0.01%	2184
2019 Q1	$271K	Buy	11,976 +2,810	+31%	+$62.1K	﹤0.01%	2050
2018 Q4	$207K	Buy	+9,166	New	+$228K	﹤0.01%	2113

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aperio Group's TVTX Position: Q4 2020 in Review

Aperio Group increased its Travere Therapeutics (TVTX) stake by 4.2% in Q4 2020, buying an estimated $15.2K and bringing the position to 15,981 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

Aperio Group first reported a position in TVTX in Q4 2018 and has held it in 9 quarters since. 138 funds tracked by Wall St. Rank hold TVTX as of Q4 2020.

Aperio Group held 15,981 shares of Travere Therapeutics worth $436K as of Q4 2020.
Aperio Group bought 650 Travere Therapeutics shares in Q4 2020, an estimated $15.2K.
Travere Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2032 holding.
Aperio Group first reported a position in Travere Therapeutics in Q4 2018 and has held it in 9 quarters since.
138 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.